Vireo Growth (VREOF) Share-based Compensation (2020 - 2026)
Vireo Growth's (VREOF) quarterly Share-based Compensation came in at $7.0 million in Q1 2026, up 438.46% year-on-year from $1.3 million in Q1 2025, and up 100.87% quarter-over-quarter from $3.5 million in Q4 2025.
Vireo Growth (VREOF) Share-based Compensation (2020 - 2026) Analysis & Trends
Vireo Growth has disclosed Share-based Compensation across 7 years of filings, most recently posting $7.0 million for Q1 2026.
- Share-based Compensation for Q1 2026 came in at $7.0 million, up 438.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.6 million (up 260.04% YoY), and the FY2025 annual result was $12.9 million, up 265.96% from the prior year.
- Share-based Compensation came in at $7.0 million for Q1 2026 at Vireo Growth, up from $3.5 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $7.0 million in Q1 2026 to a low of -$60751.0 in Q2 2024.
- The 5-year median for Share-based Compensation is $469198.0 (2022), against an average of $1.4 million.
- Peak annual rise in Share-based Compensation reached 18155.08% in 2024, while the deepest fall reached 132.21% in 2024.
- Vireo Growth's Share-based Compensation stood at $248629.0 in 2022, then sank by 40.4% to $148183.0 in 2023, then surged by 1326.37% to $2.1 million in 2024, then soared by 64.87% to $3.5 million in 2025, then soared by 100.87% to $7.0 million in 2026.
- The last three Share-based Compensation figures came in at $7.0 million (Q1 2026), $3.5 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 43.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 25.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 33.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -395,114.54 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 57.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 21.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 36.33 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 36.86 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 16.04 Mn |
| 10 | Vireo Growth | - | - | 59.30 Mn | 7.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.00 Mn |
| Mar 31, 2026 | 7.00 Mn |
| Dec 31, 2025 | 3.48 Mn |
| Dec 31, 2025 | 3.48 Mn |
| Sep 30, 2025 | 3.88 Mn |
| Sep 30, 2025 | 3.88 Mn |
| Jun 30, 2025 | 185,345.00 |
| Jun 30, 2025 | 185,345.00 |
| Mar 31, 2025 | 1.30 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 2.11 Mn |
| Dec 31, 2024 | 2.11 Mn |
| Sep 30, 2024 | 689,704.00 |
| Sep 30, 2024 | 689,704.00 |
| Jun 30, 2024 | -60,751.00 |
| Jun 30, 2024 | -60,751.00 |
| Mar 31, 2024 | 179,789.00 |
| Mar 31, 2024 | 179,789.00 |
| Dec 31, 2023 | 148,183.00 |
| Dec 31, 2023 | 148,183.00 |